文献速递脊柱关节炎

早期寡关节型银屑病关节炎向多关节型进展及阿普米司特的疾病修饰作用:FOREMOST研究新见解

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOST.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

FOREMOST研究(NCT03747939)将308例早期(平均病程9.9个月)寡关节型银屑病关节炎患者随机分配至阿普米司特或安慰剂治疗24周,随后开放标签阿普米司特至48周。结果显示,第16周时25.1%(59/235)患者进展为多关节型,阿普米司特较安慰剂降低进展风险58%(OR 0.42,95%CI 0.22-0.77);在安慰剂组中,女性、未使用过csDMARD及指趾炎显著增加进展风险。

要点

  • 阿普米司特较安慰剂降低寡关节型向多关节型进展风险58%(OR 0.42,95%CI 0.22-0.77)。
  • 安慰剂组中女性、csDMARD初治及指趾炎显著增加进展风险。
  • 阿普米司特治疗至48周维持低进展率并改善疾病活动度,无新安全信号。

核心结论

  • 在银屑病关节炎早期寡关节阶段起始阿普米司特可降低疾病活动度并延缓向多关节型进展,获益维持至48周。

研究设计与样本

  • FOREMOST(NCT03747939)随机对照试验,纳入308例早期(平均病程9.9个月)寡关节型银屑病关节炎患者,随机接受阿普米司特或安慰剂24周,随后开放标签阿普米司特至48周。
  • 采用多变量logistic回归模型分析第16周从寡关节型(≤4个活动关节)进展为多关节型(>4个活动关节)的预测因素及阿普米司特效应。
  • 共有291例患者接受至少1剂阿普米司特(从随机化或安慰剂转换),总结至48周的疾病进展、疾病活动度、临床体征/症状及耐受性。

主要发现

  • 基线时大多数(268/308 [87.0%])患者为寡关节型银屑病关节炎;第16周时25.1%(59/235)进展为多关节型(观测数据分析)。
  • 阿普米司特较安慰剂降低进展风险58%(OR 0.42,95%CI 0.22-0.77)。
  • 在安慰剂治疗患者中,女性(OR 3.35,95%CI 1.20-9.34)、csDMARD初治(OR 3.42,95%CI 1.18-9.93)及指趾炎(OR 9.26,95%CI 1.32-65.09)显著增加进展风险。
  • 阿普米司特治疗至48周维持低疾病进展率并改善疾病活动度/临床体征和症状,无新安全信号。

关键数值与推荐

  • 寡关节型定义为≤4个活动关节(肿胀和/或压痛),多关节型定义为>4个活动关节。
  • 进展预测因素包括女性(OR 3.35,95%CI 1.20-9.34)、csDMARD初治(OR 3.42,95%CI 1.18-9.93)及指趾炎(OR 9.26,95%CI 1.32-65.09)。
  • 阿普米司特降低进展的OR为0.42(95%CI 0.22-0.77)。

临床怎么用

  • 对于早期寡关节型银屑病关节炎患者,可考虑起始阿普米司特以降低疾病活动度并延缓向多关节型进展。
  • 女性、csDMARD初治及指趾炎患者进展风险较高,应密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Data regarding progression from oligoarticular to polyarticular psoriatic arthritis (PsA) are sparse. Using FOREMOST, we identify progression predictors and evaluate apremilast's treatment effect in early PsA. METHODS: FOREMOST (NCT03747939) randomized N = 308 patients with early (mean duration, 9.9 months) PsA and limited joint involvement (>1 to ≤4 swollen and >1 to ≤4 tender joints; not confirmed by imaging) to apremilast or placebo for 24 weeks, followed by open-label apremilast through week 48. Multivariable logistic regression modelled predictors of progression from oligoarticular (≤4 active [swollen and/or tender] joints) to polyarticular (>4 active joints) PsA at week 16 and the effect of apremilast. Disease progression, disease activity, clinical signs/symptoms and tolerability were summarized through week 48 for N = 291 patients receiving ≥1 apremilast dose (from randomization or switched from placebo). RESULTS: Most (268/308 [87.0%]) patients had oligoarticular PsA at baseline; 25.1% (59/235) progressed to polyarticular PsA by week 16 (data as observed). Apremilast reduced odds of progression vs placebo by 58% (odds ratio [OR; 95% CI]: 0.42 [0.22, 0.77]). In placebo-treated patients, being female, being csDMARD-naïve, and having dactylitis significantly increased odds of progression (OR: 3.35 [1.20, 9.34], 3.42 [1.18, 9.93], and 9.26 [1.32, 65.09], respectively). Apremilast treatment for up to 48 weeks maintained low rates of disease progression and improvements in disease activity/clinical signs and symptoms, with no new safety signals. CONCLUSION: Initiating apremilast treatment during the early, oligoarticular phase of PsA reduced disease activity and delayed progression to polyarticular disease, with benefits maintained with up to 48 weeks of treatment. TRIAL REGISTRATION: ClinicalTrials.gov; NCT03747939.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Coates LC, Gladman DD, Merola JF, et al. Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOST. Rheumatology (Oxford). 2026. PMID: 42384964. doi:10.1093/rheumatology/keag351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。